# Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study

**Erkan Kilic**<sup>1</sup>, Gamze Kilic <sup>2</sup>, Kemal Nas <sup>3</sup>, Betul Sargin <sup>4</sup>, Sevtap Acer Kasman <sup>5</sup>, Hakan Alkan <sup>6</sup>, Nilay Sahin <sup>7</sup>, Gizem Cengiz <sup>8</sup>, Nihan Cuzdan <sup>9</sup>, Ilknur Albayrak Gezer <sup>10</sup>, Dilek Keskin <sup>11</sup>, Cevriye Mulkoglu <sup>12</sup>, Hatice Resorlu <sup>13</sup>, Ismihan Sunar <sup>14</sup>, Ajda Bal <sup>15</sup>, Mehmet Tuncay Duruoz <sup>5</sup>, Okan Kucukakkas <sup>16</sup>, Ozan Volkan Yurdakul <sup>16</sup>, Meltem Alkan Melikoglu <sup>17</sup>, Yildiray Aydin <sup>3</sup>, Fikriye Figen Ayhan <sup>18</sup>, Hatice Bodur <sup>19</sup>, Mustafa Calis <sup>8</sup>, Erhan Capkin <sup>20</sup>, Gul Devrimsel <sup>21</sup>, Kevser Gök <sup>22</sup>, Sami Hizmetli <sup>23</sup>, Ayhan Kamanli <sup>3</sup>, Yasar Keskin <sup>16</sup>, Hilal Kocabas <sup>24</sup>, Oznur Kutluk <sup>25</sup>, Nesrin Sen <sup>26</sup>, Omer Faruk Sendur <sup>27</sup>, Ibrahim Tekeoglu <sup>3</sup>, Sena Tolu <sup>28</sup>, Murat Toprak <sup>29</sup> and Tiraje Tuncer <sup>25</sup>, <sup>1</sup>Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, <sup>2</sup>Karadeniz Technical University School of Medicine, Department of Physical Medicine and Rehabilitation, Trabzon, <sup>3</sup>Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, <sup>4</sup>Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, <sup>5</sup>Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, <sup>6</sup>Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, <sup>7</sup>Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, <sup>8</sup>Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, <sup>9</sup>Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, <sup>10</sup>Selçuk University School of Medicine, PMR Department, Konya, Turkey, <sup>11</sup>Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, <sup>12</sup>Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, <sup>13</sup>Canakkale Onsekiz Mart University School of Medicine, PMR Department, Canakkale, Turkey, <sup>14</sup>Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Turkey, <sup>15</sup>Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, <sup>16</sup>Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, <sup>17</sup>Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, <sup>18</sup>Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, <sup>19</sup>Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, <sup>20</sup>Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, <sup>21</sup>Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, <sup>22</sup>Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, <sup>23</sup>Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, <sup>24</sup>Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, <sup>25</sup>Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, <sup>26</sup>Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, <sup>27</sup>Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, <sup>28</sup>Medipol University School of Medicine, PMR Department, İstanbul, Turkey, <sup>29</sup>Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey

**Meeting: 2019 ACR/ARP Annual Meeting** 

Keywords: disease burden and climate, Psoriatic arthritis, regional difference

## **SESSION INFORMATION**

Date: Tuesday, November 12, 2019 Session Type: Poster Session (Tuesday)

Session Title: Spondyloarthritis Including Psoriatic Arthritis - Clinical Poster III: Psoriatic Arthritis, Clinical Features Session Time: 9:00AM-11:00AM

**Background/Purpose:** Psoriatic arthritis (PsA) has been defined as an inflammatory arthritis associated with psoriasis. The disease activity can be evaluated using many scales in patients with PsA. There is a great temperature difference between geographic region in Turkey. For example, the average annual air temperature in Erzurum (one of the Eastern Anatolian cities) is 5.7° C whereas in Antalya (one of the Mediterranean region cities) average temperature is 18.7° C. Furthermore, altitude of Eastern Anatolian cities is higher than Mediterranean cities. The aim of this study was to assess whether there are regional differences in disease burden in

patients with PsA.

**Methods:** Patients with PsA over the age of 18 who met the CASPAR classification criteria were enrolled consequently in this multicenter cross-sectional observational study. Turkish League Against Rheumatism (TLAR)- Network was formed with the participation of 25 different centers. Patients were grouped for 7 geographic regions (Marmara, Aegean, Mediterranean, Central Anatolia, Black Sea, Eastern Anatolia and southeastern Anatolia) in Turkey. Clinical and laboratory data were recorded. PsQoL; HAQ; BASFI, VAS-fatigue, VAS-pain, patient and physician GA; DAPSA, DAS28, BASDAI, and PASI scores were assessed. Statistical analysis was performed using the SPSS v22 package program. One-way ANOVA test were used to compare 7 geographic regions. Regression analysis was used to calculate adjusted disease measures. p 50.05 was considered statistically significant.

**Results:** A total 1130 patients (36% male, 64% female) with PsA included in this study. The mean age was  $46.96 \pm 12.25$  years. The mean symptom duration was  $9.40 \pm 8.88$  years. Crude results related to disease activity, quality of life and disability were summarized in table 1. Statistically significant differences observed for age, sex and BMI between groups. Thus, adjusted values of disease activity, quality of life and disability were calculated (table 2). Eastern Anatolian patients were youngest whereas Mediterranean patient were oldest ( $40.03 \pm 13.19 \text{ vs } 50.42 \pm 11.47, \text{ p< } 0.0001$ ). Diagnostic delay time similar between groups (p:0.096). Crude VAS-pain, fatigue, PtGA, PhGA were significantly different between groups whereas this difference disappeared when adjustment for age, sex and BMI were made in table 2. Disease activity score were highest in Mediterranean region and lowest in eastern Anatolia region according to adjusted DAPSA ( $17.72 \pm 1.75 \text{ vs } 16.35 \pm 1.62, \text{ p< } 0.0001$ ), DAS28 ( $3.53 \pm 0.29 \text{ vs } 3.25 \pm 0.28 \text{ p< } 0.0001$ ) and BASDAI ( $4.12 \pm 0.48 \text{ vs } 3.80 \pm 0.49, \text{ p:0.080}$ ). Adjusted BASFI ( $2.83 \pm 0.52 \text{ vs } 2.28 \pm 0.51, \text{ p< } 0.0001$ ), PsAQoL ( $7.54 \pm 1.48 \text{ vs } 6.07 \pm 1.44, \text{ p< } 0.0001$ ) and HAQ ( $0.48 \pm 0.11 \text{ vs } 0.36 \pm 0.13, \text{ p< } 0.0001$ ) score were highest in Mediterranean region and lowest in Eastern Anatolia region. Additionally, PASI score lowest in Mediterranean region and highest in Eastern Anatolia region.

**Conclusion:** This is the first study reporting that geographic region differences may affect disease activity as well as patient characteristic in patients with PsA. Regional weather conditions such as temperature, humidity and altitude may explain the regional differences in disease activities and other clinical characteristics.

	Marmara (n:407)	Central Anatolia (n:370)	Aegean (n:138)	Mediterranea n (n:60)	Black Sea (n:59)	Eastern Anatolia (n:60)	Southeastern Anatolia (n:36)	р	Whole PsA (n:1130)
Age, year	46.12±12.05	47.94±12.04	49.01±12.99	50.42±11.47	47.58±10.35	40.03±13.19	43.33±11.18	<0.0001	46.96±12.25
Male (%)	146(35.9)	135(36.5)	51(37)	12(20)	26(44.1)	24(40.0)	13(36.1)	0.042	407(36)
BMI, kg/m2	29.16±4.90	28.69±5.09	28.91±5.80	29.79±5.45	28.71±3.99	26.33±3.57	27.87±4.63	0.002	28.79±5.04
Symptom durations, year	8.85±8.11	9.03±9.04	12.25±11.65	11.18±8.20	10.98±7.95	8.07±6.40	5.25±5.47	<0.0001	9.40±8.88
Diagnostic delay, year	2.97±4.45	2.61±4.54	3.94±5.94	2.24±3.63	3.20±3.88	2.93±4.01	2.33±3.15	0.096	2.92±4.58
VAS-pain (0-10)	4.54±2.72	4.79±2.61	4.42±2.51	4.32±2.23	4.58±2.09	4.73±2.56	7.33±2.11	<0.0001	4.69±2.62
PtGA	4.46±2.76	4.66±2.53	4.14±2.22	4.02±1.83	4.97±2.17	4.65±2.46	5.39±2.11	0.041	4.53±2.53
PhGA	3.66±2.29	4.11±2.22	3.91±2.08	3.48±1.93	3.83±1.85	4.38±2.35	5.17±2.18	<0.0001	3.92±2.22
VAS-fatigue	5.06±2.92	5.25±2.77	4.68±2.73	4.37±2.12	3.54±3.00	5.00±3.02	5.19±3.08	0.001	4.96±2.85
TJC	4.80±8.66	6.32±8.86	3.77±7.16	6.81±7.51	4.29±5.10	8.90±10.33	10.37±11.95	<0.0001	5.67±8.70
SJC	1.54±3.69	1.36±2.96	0.84±1.65	1.85±5.03	0.53±1.46	2.13±2.04	1.86±2.16	0.028	1.40±3.17
DAPSA	15.64±12.50	18.18±13.04	14.43±10.38	18.00±14.06	16.00±7.82	20.43±13.69	24.54±15.39	<0.0001	17.05±12.65
DAS28	3.32±1.21	3.35±1.26	3.42±1.09	3.41±1.27	3.23±0.94	3.82±1.23	4.24±1.32	<0.0001	3.40±1.22
BASDAI	4.32±2.47	3.91±2.41	3.12±1.85	3.44±1.65	3.37±1.30	3.63±2.05	5.03±2.11	<0.0001	3.93±2.31
BASFI	2.81±2.42	2.28±2.29	2.18±2.35	3.30±2.05	2.00±1.19	3.37±2.94	3.02±2.40	<0.0001	2.60±2.38
PASI	2.92±5.02	3.29±5.46	3.23±4.05	1.28±1.63	1.28±1.44	3.59±3.05	4.84±5.62	0.001	3.00±4.79
PsAQoL	7.52±6.33	7.28±6.44	5.61±6.26	6.88±7.01	5.22±4.64	4.22±4.85	6.75±6.12	<0.0001	6.85±6.30
HAQ	0.42±0.47	0.43±0.47	0.35±0.45	0.65±0.58	0.34±0.31	0.45±0.42	0.54±0.38	0.001	0.43±0.47

## tablo1

Table 1 Comparison of crude disease activity, quality of life and disability measures between 7 geographic regions of Turkey in patients with PsA -mean  $\pm$  SD -

	Marmara (n:407)	Central Anatolia (n:370)	Aegean (n:138)	Mediterranea n (n:60)	Black Sea (n:59)	Eastern Anatolia (n:60)	Southeastern Anatolia (n:36)	р	Whole PsA (n:1130)
VAS-pain (0-10)	4.71±0.47	4.68±0.48	4.68±0.50	4.85±0.39	4.61±0.50	4.65±0.46	4.69±0.47	0.160	4.69±0.47
PtGA	4.54±0.41	4.51±0.42	4.52±0.45	4.66±0.35	4.46±0.43	4.48±0.40	4.53±0.41	0.140	4.53±0.42
PhGA	3.93±0.25	3.91±0.25	3.92±0.27	4.01±0.21	3.88±0.26	3.88±0.24	3.91±0.25	0.088	3.92±0.25
VAS-fatigue	4.98±0.74	4.94±0.74	4.96±0.77	5.22±0.62	4.84±0.76	4.82±0.70	4.93±0.74	0.068	4.96±0.74
тлс	5.74±1.50	5.64±1.49	5.77±1.62	6.18±1.37	5.51±1.35	5.00±1.17	5.43±1.41	0.001	5.67±1.49
SJC	1.41±0.15	1.39±0.16	1.38±0.18	1.40±0.14	1.39±0.15	1.45±0.17	1.44±0.14	0.015	1.40±0.16
DAPSA	17.14±2.00	16.98±1.96	17.18±2.13	17.72±1.75	16.84±1.90	16.35±1.62	16.67±1.76	0.007	17.05±1.97
DAS28	3.41±0.33	3.40±0.33	3.43±0.33	3.53±0.29	3.36±0.30	3.25±0.28	3.34±0.32	<0.0001	3.40±0.33
BASDAI	3.95±0.56	3.92±0.56	3.92±0.60	4.12±0.48	3.87±0.56	3.80±0.49	3.89±0.54	0.080	3.93±0.56
BASFI	2.59±0.58	2.63±0.57	2.67±0.60	2.83±0.52	2.50±0.45	2.28±0.51	2.44±0.55	<0.0001	2.60±0.57
PASI	3.04±0.55	2.96±0.53	2.92±0.53	2.79±0.52	3.02±0.49	3.25±0.57	3.14±0.51	<0.0001	3.00±0.54
PsAQoL	6.88±1.71	6.86±1.68	6.96±1.76	7.54±1.48	6.68±1.44	6.07±1.44	6.55±1.62	<0.0001	6.85±1.68
HAQ	0.42+0.13	0.43+0.12	0.44+0.12	0.48+0.11	0.42+0.11	0.36+0.13	0.40+0.12	<0.0001	0.43±0.13

## tablo2

Table 2 Comparison of adjusted disease activity, quality of life and disability measures between 7 geographic regions of Turkey in patients with PsA [mean  $\pm$  SD-adjustment for age, sex and BMI-

Disclosure: E. Kilic, None; G. Kilic, None; K. Nas, None; B. Sargin, None; S. Acer Kasman, None; H. Alkan, None; N. Sahin, None; G. Cengiz, None; N. Cuzdan, None; I. Albayrak Gezer, None; D. Keskin, None; C. Mulkoglu, None; H. Resorlu, None; I. Sunar, None; A. Bal, None; M. Duruoz, ibrahim etem, 8, Abdi ibrahim, 8, Abdi Ibrahim, 8, Abvie, 2, 8, AMGEN, 8, AMGEN, Novartis, ILKO, ONKO, ibrahim Ethem, Abdi ibrahim, 8, Ibrahim Ethem, 8, ILKO, 8, Novartis, 8, ONKO, 8; O. Kucukakkas, None; O. Yurdakul, None; M. Alkan Melikoglu, None; Y. Aydin, None; F. Ayhan, None; H. Bodur, None; M. Calis, None; E. Capkin, None; G. Devrimsel, None; K. Gök, None; S. Hizmetli, None; A. Kamanli, None; Y. Keskin, None; H. Kocabas, None; O. Kutluk, None; N. Sen, None; O. Sendur, None; I. Tekeoglu, None; S. Tolu, None; M. Toprak, None; T. Tuncer, None.

#### To cite this abstract in AMA style:

Kilic E, Kilic G, Nas K, Sargin B, Acer Kasman S, Alkan H, Sahin N, Cengiz G, Cuzdan N, Albayrak Gezer I, Keskin D, Mulkoglu C, Resorlu H, Sunar I, Bal A, Duruoz M, Kucukakkas O, Yurdakul O, Alkan Melikoglu M, Aydin Y, Ayhan F, Bodur H, Calis M, Capkin E, Devrimsel G, Gök K, Hizmetli S, Kamanli A, Keskin Y, Kocabas H, Kutluk O, Sen N, Sendur O, Tekeoglu I, Tolu S, Toprak M, Tuncer T. Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10).

https://acrabstracts.org/abstract/regional-difference-in-disease-burden-among-patients-with-psoriatic-arthritis-a-multi-center-study/. Accessed January 29, 2021.

**ACR Meeting Abstracts** - https://acrabstracts.org/abstract/regional-difference-in-disease-burden-among-patients-with-psoriatic-arthritis-a-multi-center-study/